Seronegative Lambert-Eaton myasthenic syndrome
Authors:
- 10 December 2002
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Neurology
- Vol. 59 (11) , 1773-1775
Abstract
The authors characterized the clinical and immunologic features of 110 patients with Lambert-Eaton myasthenic syndrome (LEMS). Anti-P/Q-type voltage-gated calcium channels (VGCC) antibodies were detected in 85% of the patients (seropositive) but not in the rest (seronegative). Except for the indication that small cell lung carcinoma is less common in seronegative patients, no significant differences were found in the clinical characteristics of patients who had or did not have anti-P/Q-type VGCC antibodies. The results of passive transfer experiments suggest that seronegative LEMS is also an autoantibody-mediated disorder.Keywords
This publication has 10 references indexed in Scilit:
- Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodiesNature Medicine, 2001
- Specificity of ω-conotoxin MVIIC-binding and -blocking calcium channel antibodies in Lambert-Eaton myasthenic syndromeJournal of Neurology, 1999
- Calcium channel blockers and transmitter release at the normal human neurornuscular junctionNeurology, 1996
- An improved diagnostic assay for Lambert-Eaton myasthenic syndrome.Journal of Neurology, Neurosurgery & Psychiatry, 1995
- Passive transfer of seronegative myasthenia gravis to miceMuscle & Nerve, 1994
- Trends in the association of Lambert‐Eaton myasthenic syndrome with carcinomaNeurology, 1992
- Seronegative generalized myasthenia gravisNeurology, 1992
- Seronegative myasthenia gravisNeurology, 1988
- THE LAMBERT-EATON MYASTHENIC SYNDROMEBrain, 1988
- Antibodies to motor nerve terminals: an electrophysiological study of a human myasthenic syndrome transferred to mouse.The Journal of Physiology, 1983